Although further examination is necessary to determine whether or not eribulin increases ABCB1 and ABCC11 expression in clinically treated breast cancer, the induction of resistance to key breast cancer treatment drugs should be taken into consideration when designing a treatment strategy for patients with recurrent breast cancer. This evidence concerns the gene ABCC11 and breast cancer.